^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    etoposide IV

    i
    Other names: VP-16, BMY 40481, BMY-40481
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    Apply
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (NCT00792948)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2016
    Completion :
    01/06/2026
    ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (NCT06406465)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    07/30/2027
    Completion :
    07/30/2028
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6
    |
    cisplatin • etoposide IV • Beleodaq (belinostat)
    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (AALL1131) (NCT02883049)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/29/2012
    Primary completion :
    12/31/2022
    Completion :
    10/03/2025
    ABL1 • BCR • RUNX1 • KMT2A • ETV6
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (NCT03839446)
    Phase 2
    Robert Redner, MD
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    02/28/2019
    Primary completion :
    02/02/2023
    Completion :
    12/22/2024
    CD33
    |
    CD33 expression
    |
    etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    04/19/2024
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    ALK • TERT • MYCN
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (P30CA033572) (NCT03113500)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    05/25/2017
    Primary completion :
    07/16/2021
    Completion :
    08/12/2025
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous
    Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (NCT04833114)
    Phase 3
    GWT-TUD GmbH
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/30/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma (A051902) (NCT04803201)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/08/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous
    Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04665765)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/18/2021
    Primary completion :
    07/26/2022
    Completion :
    07/08/2025
    CD20
    |
    carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (A051701) (NCT03984448)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/22/2019
    Primary completion :
    04/01/2028
    Completion :
    04/01/2028
    MYC • BCL2 • BCL6
    |
    BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (NCT03126916)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/14/2018
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    MYCN
    |
    MYCN amplification
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane
    A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (NCT04293562)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/21/2020
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    FLT3
    |
    Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane
    Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (AALL1631) (NCT03007147)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/08/2017
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R
    |
    BCR-ABL1 fusion • ABL1 fusion
    |
    imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone
    Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma (NCT02176967)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/08/2014
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    MYCN
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • cyclophosphamide intravenous
    Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (NCT03533582)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/24/2018
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    SMARCB1 • AFP
    |
    AFP elevation
    |
    cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical
    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT (NCT04322318)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/19/2020
    Primary completion :
    07/01/2027
    Completion :
    07/01/2027
    TP53
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan
    A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (NCT04684368)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/13/2021
    Primary completion :
    12/21/2029
    Completion :
    12/21/2029
    NF1
    |
    AFP elevation
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous
    A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) (NCT05533775)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/16/2022
    Primary completion :
    03/30/2027
    Completion :
    11/30/2027
    CD20 • CD4
    |
    CD20 expression
    |
    carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (LCCC1637) (NCT03264131)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/11/2018
    Primary completion :
    12/15/2023
    Completion :
    12/15/2028
    TNFRSF8
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous
    Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) (NCT06717243)
    Phase N/A
    Oncology Center of Biochemical Education And Re...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/20/2025
    Primary completion :
    03/20/2028
    Completion :
    12/01/2028
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (EA5181) (NCT04092283)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    04/29/2020
    Primary completion :
    12/31/2028
    Completion :
    12/31/2028
    CD4
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV
    Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (NCT03755804)
    Phase 2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    12/12/2018
    Primary completion :
    01/01/2027
    Completion :
    07/01/2028
    TNFRSF8
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone
    Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (ECOG-ACRIN E1910) (NCT02003222)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    05/19/2014
    Primary completion :
    06/23/2023
    Completion :
    03/14/2025
    ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors (GETUG 13) (NCT00104676)
    Phase 3
    UNICANCER
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    11/26/2003
    Primary completion :
    03/29/2012
    Completion :
    02/08/2023
    AFP
    |
    cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin
    Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (AEWS1221) (NCT02306161)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/12/2014
    Primary completion :
    03/31/2021
    Completion :
    09/19/2025
    EGFR
    |
    doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)
    Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (NCT02337985)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/20/2015
    Primary completion :
    10/02/2025
    Completion :
    10/02/2025
    CD34
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim) • cyclophosphamide intravenous
    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant (NCT04177004)
    Phase 1
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/30/2021
    Primary completion :
    10/27/2025
    Completion :
    10/27/2025
    HLA-DRB1
    |
    cyclophosphamide • etoposide IV • sirolimus • Kepivance (palifermin)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (AALL1231) (NCT02112916)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    10/04/2014
    Primary completion :
    03/31/2020
    Completion :
    09/18/2025
    CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO
    |
    CD22 expression
    |
    cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AAML1031) (NCT01371981)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/20/2011
    Primary completion :
    03/31/2019
    Completion :
    09/30/2027
    FLT3
    |
    FLT3-ITD mutation
    |
    sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686)
    Phase 1/2
    Phanes Therapeutics
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    09/05/2023
    Primary completion :
    12/01/2027
    Completion :
    08/01/2028
    EGFR • DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • etoposide IV • peluntamig (PT217)
    A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs (PELICAN) (NCT06232564)
    Phase 2
    Imperial College London
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    07/08/2024
    Primary completion :
    03/02/2028
    Completion :
    08/02/2028
    PD-1 • VEGFA • CD34 • FOXP3
    |
    Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV
    Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (NCT03220022)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    03/16/2018
    Primary completion :
    06/20/2025
    Completion :
    06/20/2025
    CD20 • CD4
    |
    CD20 positive
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous
    Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer (SHR-1316-SCLC-LN-001) (NCT06480864)
    Phase N/A
    Yunpeng Liu
    Recruiting
    Last update posted :
    01/06/2025
    Initiation :
    08/09/2024
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    PD-L1 • IL6 • IL10
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)
    Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (PTCL13) (NCT02223208)
    Phase 1/2
    Fondazione Italiana Linfomi - ETS
    Active, not recruiting
    Last update posted :
    12/09/2024
    Initiation :
    09/01/2014
    Primary completion :
    10/01/2020
    Completion :
    02/01/2026
    TET2
    |
    TET2 mutation
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Istodax (romidepsin)
    Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (P+R-ICE) (NCT05221645)
    Phase 2
    University of Southampton
    Active, not recruiting
    Last update posted :
    12/05/2024
    Initiation :
    06/27/2022
    Primary completion :
    05/30/2026
    Completion :
    12/31/2026
    CD20
    |
    CD34 positive
    |
    Keytruda (pembrolizumab) • carboplatin • Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • carmustine
    Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) (NCT04624204)
    Phase 3
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    11/19/2024
    Initiation :
    12/08/2020
    Primary completion :
    10/28/2027
    Completion :
    10/28/2027
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • carboplatin • etoposide IV
    Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (NCI-2018-02699) (NCT03749018)
    Phase 2
    David Bond, MD
    Active, not recruiting
    Last update posted :
    11/04/2024
    Initiation :
    01/02/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PD-L1 • BCL2 • PD-1
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT) (NCT02114229)
    Phase 2
    St. Jude Children's Research Hospital
    Active, not recruiting
    Last update posted :
    10/31/2024
    Initiation :
    05/14/2014
    Primary completion :
    09/01/2025
    Completion :
    09/01/2027
    SMARCB1
    |
    SMARCA4 mutation
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • topotecan • alisertib (MLN8237) • cyclophosphamide intravenous
    Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas (NCT03586999)
    Phase 1/2
    University of Colorado, Denver
    Completed
    Last update posted :
    10/29/2024
    Initiation :
    11/07/2018
    Primary completion :
    05/26/2021
    Completion :
    09/20/2022
    ALK
    |
    ALK positive • ALK negative
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisolone
    Pembrolizumab with Combination Chemotherapy in Treating Participants with Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate (NCI-2018-01120) (NCT03582475)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    09/19/2024
    Initiation :
    12/20/2018
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • etoposide IV
    Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE) (NCT06558903)
    Phase N/A
    University Hospital, Brest
    Active, not recruiting
    Last update posted :
    08/19/2024
    Initiation :
    06/24/2021
    Primary completion :
    10/01/2021
    Completion :
    01/01/2025
    PD-L1
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV